Navigation Links
Dey L.P. to Market EMSAM(R) Skin Patch for Treatment of Major Depressive Disorder
Date:5/29/2009

PITTSBURGH, May 29 /PRNewswire-FirstCall/ -- Dey L.P., a subsidiary of Mylan Inc. (Nasdaq: MYL), today announced that it has begun to market and distribute EMSAM(R) in the U.S. EMSAM, a selegiline transdermal system, is a monoamine oxidase inhibitor (MAOI), which was approved by the U.S. Food and Drug Administration (FDA) in 2006 for the treatment of major depressive disorder.

EMSAM previously was marketed and distributed by Bristol-Myers Squibb through a commercialization agreement. The transfer of distribution, marketing and sales to Dey concludes the three-year agreement with Bristol-Myers. Manufactured by Mylan subsidiary Mylan Technologies Inc. (MTI), EMSAM is a registered trademark of Somerset Pharmaceuticals Inc. In July 2008, Mylan acquired Watson Pharmaceutical Inc.'s 50 percent interest in Somerset, making the proprietary research and development company a wholly-owned subsidiary of Mylan.

Dey President Carolyn Myers, Ph.D., said, "I am very pleased that we have the opportunity to bring the marketing and distribution of EMSAM back into the Mylan family of companies. EMSAM was developed by Somerset in collaboration with Mylan and is manufactured by MTI. Now, we can market and distribute this important product through our specialty division, Dey, and the entire supply and distribution process will benefit from additional efficiencies and cost synergies going forward."

Dey, a Mylan company, is a specialty pharmaceutical company focused on the development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases, respiratory-related allergies and emergency care medicine. As the U.S. leader in sales of nebulized respiratory medication, Dey puts patients first through its development of innovative and affordable therapies. For more information on Dey or its products, please visit www.dey.com.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generics and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest -- and highest quality -- product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
2. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
3. InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom
4. Kendle to Ring Opening Bell at NASDAQ Stock Market on August 22
5. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
6. AspenBio Pharma Shares to Trade on the NASDAQ Capital Markets Exchange Under Symbol APPY
7. DNA Sequencing Equipment Market to Fragment and Grow as Competition, New Technologies Develop
8. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
9. Dental Implant Market Insights Webinar
10. Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
11. XTL to Appeal NASDAQ Staff Determination; XTL May Transfer its ADR Listing to the NASDAQ Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Proove Biosciences, ... to announce the launch of the Proove Health Foundation . The Foundation ... to promote the use of personalized medicine for tackling the nation’s most-pressing healthcare ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Intelligent Implant ... by the FDA via 510(k) for sale in the United States. These components ... posterior thoraco-lumbar fusions. With one-level sales beginning in October of 2015, the company ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... deliver a talk on its first-in-class technologies for tissue stem cell counting and ... on RNAiMicroRNA Biology to Reprogramming & CRISPR-based Genome Engineering in Burlington, Massachusetts. , ...
(Date:4/27/2016)... ... April 27, 2016 , ... The Pittcon Organizing Committee is pleased to ... been a volunteer member of Committee since 1987. Since then, he has served in ... treasurer and was chairman for both the program and exposition committees. In his professional ...
Breaking Biology Technology:
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
(Date:3/22/2016)... India , March 22, 2016 /PRNewswire/ ... market research report "Electronic Sensors Market for Consumer ... Proximity, & Others), Application (Communication & IT, ... Geography - Global Forecast to 2022", published ... industry is expected to reach USD 26.76 ...
(Date:3/21/2016)... Massachusetts , March 22, 2016 ... facial recognition with passcodes for superior security   ... ), a leading provider of secure digital communications services, ... their biometric technology and offer enterprise customers, particularly those ... secure facial recognition and voice authentication within a mobile ...
Breaking Biology News(10 mins):